Biogen (BIIB) to Invest $2 Billion in U.S. Expansion Amid Onshoring Push

Biogen Inc. (NASDAQ:BIIB) ranks among the stocks to benefit from an onshoring boom. On July 21, Biogen Inc. (NASDAQ:BIIB) declared that it would invest $2 billion to its existing North Carolina production facilities as part of its efforts to grow in the United States in the face of tariff threats from President Donald Trump.

Biogen (BIIB) to Invest $2 Billion in U.S. Expansion Amid Onshoring Push

Although President Trump has frequently maintained that separate levies are necessary to support American manufacturing and prevent reliance on other nations for medical supplies, drugs have so far been spared from his reciprocal tariffs.

According to the company, the investments will increase Biogen’s capacity to develop and produce specific gene-targeting treatments, as well as add fill-finish facilities, automation, and artificial intelligence. Biogen Inc. (NASDAQ:BIIB) has so far invested around $10 billion in its North Carolina production.

Biogen Inc. (NASDAQ:BIIB) is a multinational biopharmaceutical company dedicated to discovering, developing, and providing innovative treatments to patients with severe complex illnesses.

While we acknowledge the potential of BIIB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIIB and that has 100x upside potential, check out our report about this cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.